Co-Diagnostics, Inc.

NasdaqCM:CODX Stock Report

Market Cap: US$23.3m

Co-Diagnostics Future Growth

Future criteria checks 0/6

Co-Diagnostics's revenue and earnings are forecast to decline at 94.5% and 8.3% per annum respectively while EPS is expected to grow by 10.6% per annum.

Key information

-8.3%

Earnings growth rate

10.6%

EPS growth rate

Medical Equipment earnings growth17.0%
Revenue growth rate-94.5%
Future return on equityn/a
Analyst coverage

Low

Last updated11 Nov 2024

Recent future growth updates

Recent updates

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

Jun 14
Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

May 18
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Apr 14
A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Co-Diagnostics: Hold Thesis Remains Well Intact

Sep 07

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Aug 11

Co-Diagnostics spikes on shipments of monkeypox test

Jul 11

Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Jul 06
Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant

Jun 21

Co-Diagnostics: Where's Eikon?

Apr 03

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 28
Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Co-Diagnostics: Swinging For The Fences

Jan 24

Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Dec 28
Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Why Co-Diagnostics Is A Solid Covid-19 Play

Aug 19

Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Aug 14
Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Earnings and Revenue Growth Forecasts

NasdaqCM:CODX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20252-44N/AN/A1
12/31/20244-37N/AN/A1
9/30/20247-41-27-26N/A
6/30/20249-38-25-24N/A
3/31/20247-39-26-25N/A
12/31/20237-35-23-22N/A
9/30/20235-43-23-21N/A
6/30/20237-38-16-14N/A
3/31/202312-32-8-7N/A
12/31/202234-1457N/A
9/30/202253151415N/A
6/30/202278282526N/A
3/31/2022101403637N/A
12/31/202198374041N/A
9/30/2021105425556N/A
6/30/202196465253N/A
3/31/202193514142N/A
12/31/202075422728N/A
9/30/2020482867N/A
6/30/20202610-3-3N/A
3/31/20202-6-6-5N/A
12/31/20190-6-6-6N/A
9/30/20190-6-5-5N/A
6/30/20190-6-5-5N/A
3/31/20190-6-5-4N/A
12/31/20180-6-4-4N/A
9/30/20180-6-4-4N/A
6/30/20180-8N/A-4N/A
3/31/20180-8N/A-4N/A
12/31/20170-7N/A-3N/A
9/30/20170-6N/A-3N/A
6/30/20170-3N/A-2N/A
3/31/2017N/A-2N/A-1N/A
12/31/2016N/A-2N/A-1N/A
9/30/20160-2N/A-1N/A
12/31/20150-2N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CODX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CODX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CODX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CODX's revenue is expected to decline over the next 3 years (-94.5% per year).

High Growth Revenue: CODX's revenue is forecast to decline over the next 3 years (-94.5% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CODX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:27
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Co-Diagnostics, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yi ChenH.C. Wainwright & Co.
James SidotiSidoti & Company, LLC